These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1092 related articles for article (PubMed ID: 26579470)

  • 21. Cancer-associated fibroblasts promote epithelial-mesenchymal transition and EGFR-TKI resistance of non-small cell lung cancers via HGF/IGF-1/ANXA2 signaling.
    Yi Y; Zeng S; Wang Z; Wu M; Ma Y; Ye X; Zhang B; Liu H
    Biochim Biophys Acta Mol Basis Dis; 2018 Mar; 1864(3):793-803. PubMed ID: 29253515
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Bim deletion polymorphism clinical profile and its relation with tyrosine kinase inhibitor resistance in Chinese patients with non-small cell lung cancer.
    Zhao M; Zhang Y; Cai W; Li J; Zhou F; Cheng N; Ren R; Zhao C; Li X; Ren S; Zhou C; Hirsch FR
    Cancer; 2014 Aug; 120(15):2299-307. PubMed ID: 24737648
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer.
    Donev IS; Wang W; Yamada T; Li Q; Takeuchi S; Matsumoto K; Yamori T; Nishioka Y; Sone S; Yano S
    Clin Cancer Res; 2011 Apr; 17(8):2260-9. PubMed ID: 21220474
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
    Shi Z; Peng XX; Kim IW; Shukla S; Si QS; Robey RW; Bates SE; Shen T; Ashby CR; Fu LW; Ambudkar SV; Chen ZS
    Cancer Res; 2007 Nov; 67(22):11012-20. PubMed ID: 18006847
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hepatocellular Carcinoma: Etiology and Current and Future Drugs.
    Jindal A; Thadi A; Shailubhai K
    J Clin Exp Hepatol; 2019; 9(2):221-232. PubMed ID: 31024205
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MiR-30a-5p Overexpression May Overcome EGFR-Inhibitor Resistance through Regulating PI3K/AKT Signaling Pathway in Non-small Cell Lung Cancer Cell Lines.
    Meng F; Wang F; Wang L; Wong SC; Cho WC; Chan LW
    Front Genet; 2016; 7():197. PubMed ID: 27895663
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Establishment and biological characteristics of acquired gefitinib resistance in cell line NCI-H1975/gefinitib-resistant with epidermal growth factor receptor T790M mutation.
    Zhao BX; Wang J; Song B; Wei H; Lv WP; Tian LM; Li M; Lv S
    Mol Med Rep; 2015 Apr; 11(4):2767-74. PubMed ID: 25483995
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth factor-induced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer.
    Wang W; Li Q; Takeuchi S; Yamada T; Koizumi H; Nakamura T; Matsumoto K; Mukaida N; Nishioka Y; Sone S; Nakagawa T; Uenaka T; Yano S
    Clin Cancer Res; 2012 Mar; 18(6):1663-71. PubMed ID: 22317763
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Implication of epithelial-mesenchymal transition in IGF1R-induced resistance to EGFR-TKIs in advanced non-small cell lung cancer.
    Zhou J; Wang J; Zeng Y; Zhang X; Hu Q; Zheng J; Chen B; Xie B; Zhang WM
    Oncotarget; 2015 Dec; 6(42):44332-45. PubMed ID: 26554308
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Primary concomitant EGFR T790M mutation predicted worse prognosis in non-small cell lung cancer patients.
    Li H; Hu H; Wang R; Pan Y; Wang L; Li Y; Zhang Y; Ye T; Zhang Y; Li B; Shen L; Sun Y; Chen H
    Onco Targets Ther; 2014; 7():513-24. PubMed ID: 24729716
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Computationally predicted SARS-COV-2 encoded microRNAs target NFKB, JAK/STAT and TGFB signaling pathways.
    Aydemir MN; Aydemir HB; Korkmaz EM; Budak M; Cekin N; Pinarbasi E
    Gene Rep; 2021 Mar; 22():101012. PubMed ID: 33398248
    [TBL] [Abstract][Full Text] [Related]  

  • 32. P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
    Katayama R; Sakashita T; Yanagitani N; Ninomiya H; Horiike A; Friboulet L; Gainor JF; Motoi N; Dobashi A; Sakata S; Tambo Y; Kitazono S; Sato S; Koike S; John Iafrate A; Mino-Kenudson M; Ishikawa Y; Shaw AT; Engelman JA; Takeuchi K; Nishio M; Fujita N
    EBioMedicine; 2016 Jan; 3():54-66. PubMed ID: 26870817
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.
    Zhang K; Yuan Q
    J Cancer Res Ther; 2016 Dec; 12(Supplement):C131-C137. PubMed ID: 28230005
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PDGFRA, PDGFRB, EGFR, and downstream signaling activation in malignant peripheral nerve sheath tumor.
    Perrone F; Da Riva L; Orsenigo M; Losa M; Jocollè G; Millefanti C; Pastore E; Gronchi A; Pierotti MA; Pilotti S
    Neuro Oncol; 2009 Dec; 11(6):725-36. PubMed ID: 19246520
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Human ATP-Binding Cassette transporters ABCB1 and ABCG2 confer resistance to CUDC-101, a multi-acting inhibitor of histone deacetylase, epidermal growth factor receptor and human epidermal growth factor receptor 2.
    Wu CP; Hsiao SH; Su CY; Luo SY; Li YQ; Huang YH; Hsieh CH; Huang CW
    Biochem Pharmacol; 2014 Dec; 92(4):567-76. PubMed ID: 25450670
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation--diversity, ductility, and destiny.
    Suda K; Mizuuchi H; Maehara Y; Mitsudomi T
    Cancer Metastasis Rev; 2012 Dec; 31(3-4):807-14. PubMed ID: 22736441
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epigenetic regulation in human melanoma: past and future.
    Sarkar D; Leung EY; Baguley BC; Finlay GJ; Askarian-Amiri ME
    Epigenetics; 2015; 10(2):103-21. PubMed ID: 25587943
    [TBL] [Abstract][Full Text] [Related]  

  • 38. c-Met expression in renal cell carcinoma with bone metastases.
    Silva Paiva R; Gomes I; Casimiro S; Fernandes I; Costa L
    J Bone Oncol; 2020 Dec; 25():100315. PubMed ID: 33024658
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Norcantharidin combined with EGFR-TKIs overcomes HGF-induced resistance to EGFR-TKIs in EGFR mutant lung cancer cells via inhibition of Met/PI3k/Akt pathway.
    Wu H; Fan F; Liu Z; Shen C; Wang A; Lu Y
    Cancer Chemother Pharmacol; 2015 Aug; 76(2):307-15. PubMed ID: 26063323
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long non-coding RNA BC087858 induces non-T790M mutation acquired resistance to EGFR-TKIs by activating PI3K/AKT and MEK/ERK pathways and EMT in non-small-cell lung cancer.
    Pan H; Jiang T; Cheng N; Wang Q; Ren S; Li X; Zhao C; Zhang L; Cai W; Zhou C
    Oncotarget; 2016 Aug; 7(31):49948-49960. PubMed ID: 27409677
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 55.